Patricia Carr Sells 5,319 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 5,319 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $182.06, for a total value of $968,377.14. Following the completion of the transaction, the chief accounting officer owned 7,012 shares of the company’s stock, valued at $1,276,604.72. The trade was a 43.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Jazz Pharmaceuticals Stock Up 0.7%

JAZZ opened at $176.93 on Friday. The company has a market capitalization of $10.75 billion, a P/E ratio of -26.29, a P/E/G ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The firm’s fifty day moving average price is $138.86 and its two-hundred day moving average price is $122.36. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.11 billion. During the same quarter in the prior year, the company posted $6.54 EPS. The business’s revenue was up 6.7% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analysts Set New Price Targets

JAZZ has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research note on Monday, October 27th. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Morgan Stanley boosted their price target on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the company an “overweight” rating in a research note on Monday, November 17th. The Goldman Sachs Group upped their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $195.07.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of JAZZ. Dimensional Fund Advisors LP boosted its stake in Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after purchasing an additional 298,815 shares in the last quarter. Capital World Investors raised its holdings in shares of Jazz Pharmaceuticals by 0.4% in the third quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company’s stock valued at $336,731,000 after buying an additional 10,345 shares during the last quarter. LSV Asset Management lifted its position in Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after buying an additional 87,576 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after acquiring an additional 191,637 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Jazz Pharmaceuticals by 8.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after acquiring an additional 145,865 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.